SAN CARLOS, Calif., October 12, 2023 – Glycomine, Inc., a clinical-stage biotechnology company focused on developing new therapies for serious orphan diseases, announced the appointment of Rose Marino, M.D. as Chief Medical Officer. Dr. Marino has more than 20 years of collective experience in academic medicine and clinical development in the pharmaceutical industry, with specialized training in pediatrics and pediatric endocrinology.  

“Rose’s deep expertise in pediatric endocrinology and experience in clinical research in rare diseases, will be a critical asset in the advancement of our lead drug candidate, GLM101, currently in Phase 2 clinical studies,” said Steven Axon, Chief Executive Officer of Glycomine. “I look forward to working closely with her as we seek to deliver important clinical validation in the development of GLM101, which we believe will be the first disease-modifying treatment for PMM2-CDG.”

Dr. Marino added, “Joining Glycomine is an opportunity to positively impact the lives of those affected by PMM2-CDG. I see the potential to improve not only the lives of patients but also their family members and caretakers. I am excited to further propel the research at Glycomine as we advance our clinical studies with GLM101.”

Prior to Glycomine, Dr. Marino was Vice President of Clinical Development at Ipsen, a biopharmaceutical company focused on developing and commercializing innovative medicines for oncology, rare diseases, and neuroscience. Dr. Marino was the medical lead for the palovarotene clinical development program for fibrodysplasia ossificans progressiva, overseeing the pivotal program through final FDA approval. Prior to her work at Ipsen, she worked in progressive leadership positions in clinical development at Clementia Pharmaceuticals and Alkermes. In addition to her roles in industry, Dr. Marino has more than a decade of clinical experience as a pediatric endocrinologist at Massachusetts General Hospital. Prior to that, she was a Research Fellow in Pediatric Endocrinology at the National Institutes of Health and a Clinical Fellow at Johns Hopkins Hospital. Dr. Marino completed her residency in pediatrics at Loyola University Medical Center, and received an M.D. from SUNY Stony Brook School of Medicine and a B.S. in chemical engineering from Massachusetts Institute of Technology.  

About Glycomine, Inc.

Glycomine is a clinical-stage biotechnology company developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company’s approach is to use replacement therapies – substrates, enzymes, or proteins – and to target those molecules to clinically relevant cellular compartments. The company is based in San Carlos, California and supported by leading international life sciences investors. For more information, visit www.glycomine.com.

Corporate Contact: Steven Axon, CEO, Glycomine Inc., info@glycomine.com

Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com,  +1.858.344.8091